| Literature DB >> 3924714 |
J Fujita, N Saijo, K Eguchi, E Shimizu, T Shinkai, K Tominaga, Y Sasaki, H Futami, M Sakurai, A Hoshi.
Abstract
A phase II study of cis-diamminedichloroplatinum (CDDP, 80 mg/m2, every 3 weeks) was performed in patients with non-small cell lung cancer (NSCLC). The overall response rate to CDDP was 14% (6/42). In patients without prior chemotherapy, the response rate was 20% (2/10), and in patients with prior chemotherapy, the response rate was 13% (4/31). The major side effect was gastrointestinal toxicity. It was concluded that CDDP at a dose of 80 mg/m2 every 3 weeks is effective against NSCLC.Entities:
Mesh：
Substances：
Year: 1985 PMID： 3924714
Source DB: PubMed Journal: Jpn J Cancer Res ISSN： 0910-5050